GW Pharma says cannabis drug helps MS sufferers

GW Pharmaceuticals Plc said on Tuesday its cannabis-based medicine Sativex was effective in reducing pain-related problems for patients suffering from multiple sclerosis.

The company said a study based on 66 patients found Sativex was significantly superior to placebo in reducing pain and sleep disturbance.

Sativex, an under-the-tongue cannabis spray, has been developed by GW Pharmaceuticals and is currently approved as a prescription medicine in Canada for the symptomatic relief of neuropathic pain in adults with multiple sclerosis.

An ongoing clinical trial programme is being undertaken to support regulatory approval in the UK. Upon UK approval, Sativex will be exclusively marketed by Germany’s Bayer AG, GW said. UK approval is viewed as crucial, as it would open the door to the larger European market. 

Print Version
Tell-a-Friend

RELATED ARTICLES:

Personal rehab helpful for multiple sclerosis   Obesity, other health problems delay MS diagnosis   Physical activity may lessen stroke severity   Stroke Onset Needs to be Treated Like the Emergency Situation It Is   Response to immune protein determines pathology of multiple sclerosis   Occasional Memory Loss Tied to Lower Brain Volume   Neurotransmitter defect may trigger autoimmune disease   Nerve Activity Can Predict Life Or Death for Comatose Patients   New marker for raised intracranial pressure   Treatment for Parkinson’s examined   Pain appears common among patients with Parkinson’s disease   Chronic stress alters our genetic immune response